ICU Medical (ICUI) officer Daniel Woolson sells 5,417 shares at $181.33

Rhea-AI Filing Summary

ICU Medical Inc. (ICUI) officer Daniel Woolson, VP and GM-Infusion Capital, reported a sale of 5,417 shares of common stock on August 13, 2026 at $181.33 per share. Following this transaction, he directly holds 17,062 shares of ICU Medical common stock. The Rule 10b5-1 trading plan checkbox was not marked.

Insider Trade Summary

Net Seller: 5,417 shares

Net Sell 1 txn

Insider Woolson Daniel

Role VP, GM-Infusion Capital

Sold 5,417 shs ($982K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	5,417	$181.33	$982K

Holdings After Transaction: Common Stock — 17,062 shares (Direct)

Footnotes (1)

1. F1. All shares sold were sold at the exact price disclosed.

Key Figures

Shares sold: 5,417 shares Sale price per share: $181.33 per share Shares owned after transaction: 17,062 shares +1 more

4 metrics

Shares sold 5,417 shares Common stock sale on August 13, 2026 by officer Daniel Woolson

Sale price per share $181.33 per share All shares sold at this exact price per Form 4 footnote

Shares owned after transaction 17,062 shares Directly held ICU Medical common stock following the reported sale

Transactions reported as sales 1 transaction Form 4 transaction summary shows one non-derivative sale

Key Terms

Rule 10b5-1, non-derivative, direct ownership, open market or private transaction

4 terms

Rule 10b5-1 regulatory

"The Rule 10b5-1 trading plan checkbox was not marked"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

non-derivative financial

"The transaction was classified as non-derivative common stock"

direct ownership financial

"These holdings are reported as direct ownership in the Form 4"

open market or private transaction financial

"Transaction code description notes sale in open market or private transaction"

FAQ

What insider transaction did ICU Medical (ICUI) report for Daniel Woolson?

ICU Medical reported that officer Daniel Woolson sold 5,417 shares of common stock on August 13, 2026 at $181.33 per share. The filing classifies this as a sale of non-derivative common stock.

At what price were the ICUI shares sold in Daniel Woolson’s Form 4?

The shares were sold at $181.33 per share, and a footnote states all shares were sold at this exact price. The transaction involved non-derivative common stock of ICU Medical Inc.

How many ICU Medical (ICUI) shares does Daniel Woolson hold after the reported sale?

After the reported sale, Daniel Woolson directly holds 17,062 shares of ICU Medical common stock. These holdings are reported as direct ownership in the Form 4 filing’s post-transaction balance field.

Was Daniel Woolson’s ICUI share sale under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is marked false, indicating the transaction was not reported as being effected under a Rule 10b5-1 trading plan. No trading-plan footnote is provided for this sale.

What role does Daniel Woolson hold at ICU Medical (ICUI) in this Form 4?

In the Form 4, Daniel Woolson is identified as an officer of ICU Medical with the title VP, GM-Infusion Capital. He is not listed as a director or ten percent owner in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/13/2026 - 06:56 PM Accepted by SEC EDGAR 08/13/2026 - 06:56 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Woolson Daniel

(Last) (First) (Middle)

951 CALLE AMANECER

(Street)

SAN CLEMENTE CALIFORNIA 92673

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ICU MEDICAL INC/DE [ ICUI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, GM-Infusion Capital

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2026		S		5,417	D	$181.33(1)	17,062	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All shares sold were sold at the exact price disclosed.

	By: Paula Darbyshire, Attorney-in-Fact For: Daniel Woolson	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)